Structural heart disease (SHD) is a congenital defect normally seen in children or adults. More than 70,000 children in the European Union (EU) and the U.S. are reportedly afflicted with SHD annually. The three common defects associated with SHD are patent foramen of ovale (PFO), coarctation of the aorta, and atrial septal defect (ASD). Developments in MRI have led to dosage reduction of radiation making it a preferable option for diagnosing children and pregnant women.
Echocardiogram to Emerge as the Biggest Segment by 2025
Structural heart imaging (SHI) consists of imaging technologies used to identify structural heart diseases. These technologies include echocardiogram, magnetic resonance imaging (MRI), and computed tomography (CT). The echocardiogram segment is anticipated to be the biggest segment by 2025 due to its capacity to generate high-quality images of internal vessels of the heart. The segment is witnessing impressive innovations in terms of technology. For instance, Siemens Healthineers has introduced the Acuson SC2000 Prime Edition that utilizes transesophageal echocardiography (TEE). This machine can assist surgeons or diagnosticians in offering accurate solutions to SHD-prone patients.
The MRI segment, on the other hand, is expected to grow at a rapid rate till 2025 due to technological improvements in MRI devices. The Signa Premier by GE Healthcare is a prime example of advanced MRI technology. It is expected to be used in diagnosing more complex forms of congenital heart diseases after gaining approval from the U.S. Food and Drug Administration (FDA).
Market Overview
According to Grand View Research, Inc.; the global structural heart imaging (SHI) market is expected to reach a market size above USD 25 billion by 2025. Rising incidence of structural heart disease among children and adults is the primary market driver. Advancements in imaging technologies are anticipated to spur market growth. Introduction of minimally advanced technologies such as transcatheter mitral valve repair (TMVR) and transcatheter aortic valve repair (TAVR) are projected to open up new avenues for market growth.
High cost of interventional surgical procedures may act as a market deterrent in near future. Key market players include Siemens Healthineers; Shimadzu Corporation; HeartSciences; and TomTec Imaging Systems GmbH. The future of the market largely depends on the adoption of 3D imaging technologies. Technologies like 3D transesophageal echocardiography (TOE) and mult-slice computed tomography (MSCT) can play a vital role in increasing the success rate of operations.
Access full research report at:
Access full research report at:
1 comment:
I think this is one of the most significant info for me.
Bovine Pericardium Tissue
TMVR Contract Manufacturing
Post a Comment